

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 December 2009 (10.12.2009)

PCT

(10) International Publication Number
WO 2009/148575 A8

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/00 (2006.01)
C12N 5/16 (2006.01)

(21) International Application Number:

PCT/US2009/003355

(22) International Filing Date:

1 June 2009 (01.06.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/057,586	30 May 2008 (30.05.2008)	US
61/121,391	10 December 2008 (10.12.2008)	US
61/178,350	14 May 2009 (14.05.2009)	US

(71) Applicant (for all designated States except US):
XBIOTECH, INC. [CA/CA]; 1055 West Hastings Street,
Suite 300, Vancouver, BC, V6E 2E9 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SIMARD, John** [CA/
US]; 8201 East Riverside Drive, Bldg. # 4, Suite 100,
Austin, TX 78744 (US).

(74) Agent: **KIM, Stanley, A.**; 3319 State Road 7, Suite 301,
Wellington, FL 33449, US (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,
SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR),
OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

5 August 2010

(15) Information about Correction:

see Notice of 5 August 2010

(54) Title: IL-1 α ABS AND METHODS OF USE

(57) Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1 α and (ii) a constant region that is effective at both activating the complement system through C1q binding and binding to several different Fc receptors.



WO 2009/148575 A8